These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34159509)

  • 41. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents.
    Duchini G; Itin P; Arnold A
    Adv Skin Wound Care; 2011 May; 24(5):217-20. PubMed ID: 21505282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes.
    Permaul P; Narla A; Hornick JL; Pai SY
    Immunol Res; 2009; 44(1-3):89-98. PubMed ID: 19225723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interventions for psoriatic arthritis.
    Jones G; Crotty M; Brooks P
    Cochrane Database Syst Rev; 2000; (3):CD000212. PubMed ID: 10908464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.
    Nordström DC; Konttinen L; Korpela M; Tiippana-Kinnunen T; Eklund K; Forsberg S; Ilva K; Kaipiainen-Seppänen O; Malmi T; Ylä-Kerttula T; Honkanen V
    Rheumatol Int; 2006 Jun; 26(8):741-8. PubMed ID: 16205925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra.
    Cattalini M; Meini A; Monari P; Gualdi G; Arisi M; Pelucchi F; Bolognini S; Gattorno M; Calzavara-Pinton PG; Plebani A
    Dermatol Online J; 2013 Nov; 19(11):20405. PubMed ID: 24314780
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Relationship between NALP3 and Autoinflammatory Syndromes.
    Campbell L; Raheem I; Malemud CJ; Askari AD
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187378
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs.
    Khanna R; Jairath V; Feagan BG
    Gastroenterol Clin North Am; 2017 Sep; 46(3):661-677. PubMed ID: 28838421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
    Rivera-Rodriguez L; Pardo-Díaz E; Moreno-Espinosa S; Scheffler-Mendoza S; Ruiz-Ontiveros MA; Garrido-García LM; Iglesias-Amaya A; Yamazaki-Nakashimada MA
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e448-e451. PubMed ID: 32079989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetics and inflammatory bowel disease: progress and prospects.
    Ho GT; Lees C; Satsangi J
    Inflamm Bowel Dis; 2004 Mar; 10(2):148-58. PubMed ID: 15168816
    [No Abstract]   [Full Text] [Related]  

  • 50. Immunosuppressive agents in penetrating keratoplasty.
    Barraquer J
    Am J Ophthalmol; 1985 Jul; 100(1):61-4. PubMed ID: 3893140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Therapeutic strategies for cutaneous sarcoidosis].
    Bäcker H; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2005 Apr; 3(4):284-97; quiz 298-300. PubMed ID: 16370479
    [No Abstract]   [Full Text] [Related]  

  • 52. [Chronic inflammatory bowel diseases. Immunosuppressive drugs--good alternatives to steroids].
    MMW Fortschr Med; 2001 Jul; 143(26-27):54-6. PubMed ID: 11481920
    [No Abstract]   [Full Text] [Related]  

  • 53. [Correlations between the histological changes and results of treatment with corticoids and immunosuppressive agents in primary glomerulonephritis].
    Lagrue G; Bariety J
    Minerva Med; 1970 Jul; 61(55):3054-63. PubMed ID: 5427678
    [No Abstract]   [Full Text] [Related]  

  • 54. The body against self: autoinflammation and autoimmunity.
    Borella E; Palma L; Zen M; Bettio S; Nalotto L; Gatto M; Domeneghetti M; Laccarino L; Punzi L; Doria A
    Isr Med Assoc J; 2014 Oct; 16(10):608-10. PubMed ID: 25438443
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pyoderma gangrenosum and Sweet's syndrome : Cutaneous manifestations of autoinflammatory disorders].
    Meier B; Maul JT; French LE
    Hautarzt; 2016 Dec; 67(12):934-939. PubMed ID: 27796411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Uveitic macular edema and the pharmacotherapy].
    Liu X; Zhang M
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):151-4. PubMed ID: 25908007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist.
    Stenerson M; Dufendach K; Aksentijevich I; Brady J; Austin J; Reed AM
    Arthritis Rheum; 2011 Dec; 63(12):4018-22. PubMed ID: 21792839
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Immunosuppressive agents in the treatment of rheumatoid diseases].
    Popović M; Vrbanec D
    Vojnosanit Pregl; 1981; 38(4):259-66. PubMed ID: 6974427
    [No Abstract]   [Full Text] [Related]  

  • 59. IL-1 blockade in autoinflammatory syndromes.
    Jesus AA; Goldbach-Mansky R
    Annu Rev Med; 2014; 65():223-44. PubMed ID: 24422572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Autoimmune diseases and immunosuppressive therapy. I. Immunosuppressive agents].
    Delespesse G; Kennes B; Duchateau J
    Acta Clin Belg; 1974; 29(5):321-8. PubMed ID: 4440395
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.